Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Recombinant human erythropoietin (rhEPO) is receiving increasing attention as a potential therapy for prevention of injury and restoration of function in nonhematopoietic tissues. However, the minimum effective dose required to mimic and augment these normal paracrine functions of erythropoietin (EPO) in some organs (e.g., the brain) is higher than for treatment of anemia. Notably, a dose-dependent risk of adverse effects has been associated with rhEPO administration, especially in high-risk groups, including polycythemia–hyperviscosity syndrome, hypertension, and vascular thrombosis. Of note, several clinical trials employing relatively high dosages of rhEPO in oncology patients were recently halted after an increase in mortality and morbidity, primarily because of thrombotic events. We recently identified a heteromeric EPO receptor complex that mediates tissue protection and is distinct from the homodimeric receptor responsible for the support of erythropoiesis. Moreover, we developed receptor-selective ligands that provide tools to assess which receptor isoform mediates which biological consequence of rhEPO therapy. Here, we demonstrate that rhEPO administration in the rat increases systemic blood pressure, reduces regional renal blood flow, and increases platelet counts and procoagulant activities. In contrast, carbamylated rhEPO, a heteromeric receptor-specific ligand that is fully tissue protective, increases renal blood flow, promotes sodium excretion, reduces injury-induced elevation in procoagulant activity, and does not effect platelet production. These preclinical findings suggest that nonerythropoietic tissue-protective ligands, which appear to elicit fewer adverse effects, may be especially useful in clinical settings for tissue protection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Erythropoietin was originally recognized via its role in erythropoiesis [2145-2147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940,942,2148-”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [2153]
Citations
Cites
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 2,005
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Kalantar-Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,148
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich, F., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402029 · Cited by 1,028
Self-citationDerivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic
Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., et al. (2004) · Science · doi:10.1126/science.1098313 · Cited by 803
Self-citationErythropoietin: Physiology and Pharmacology Update
Fisher, J. W. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800101 · Cited by 708
Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli, M., Latini, R., Xie, Q.-W., Smart, J., Su-Rick, C.-J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406491101 · Cited by 656
Self-citationRisk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study
Khorana, A. A., Francis, C. W., Culakova, E., & Lyman, G. H. (2005) · Cancer · doi:10.1002/cncr.21496 · Cited by 565
Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., Viviani, B., Marinovich, M., Cerami, A., Coleman, T. R., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021067 · Cited by 527
Self-citation
Research works printed but not linked: 7
- D. Santini, B. Vincenzi, A. La Cesa, V. Virzi, F. Navajas, V. Malafarina, G. Dicuonzo, R. Cassandro, V. Esposito, V. Montesarchio, et al. Anticancer Res 25, 669–674 (2005).
- 10.1002/1097-0320(20000701)40:3<173::AID-CYTO1>3.0.CO;2-L · doi:10.1002/1097-0320(20000701)40:3<173::aid-cyto1>3.0.co;2-l
- N. D. Vaziri, X. J. Zhou, J. Smith, F. Oveisi, K. Baldwin, R. E. Purdy Am. J. Physiol 269, F838–F845 (1995).
- M. Nowicki J. Hum. Hypertens 9, 81–88 (1995).
- A. Lin, J. Ryu, D. Harvey, B. Sieracki, S. Scudder, T. Wun Gynecol. Oncol, 2006).
- 10.1016/S0008-6363(96)00066-1 · doi:10.1016/s0008-6363(96)00066-1 · Paper page
- 10.1093/oxfordjournals.ndt.a027361 · doi:10.1093/oxfordjournals.ndt.a027361 · Paper page
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Brines, M., & Cerami, A. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02024.x · Cited by 333
Self-citationDiscovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise
Brines, M., & Cerami, A. (2006) · Kidney International · doi:10.1038/sj.ki.5001546 · Cited by 290
Self-citationFrom oxygen to erythropoietin: Relevance of hypoxia for retinal development, health and disease
Caprara, C., & Grimm, C. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.003 · Cited by 176
Metadata
- Authors
- Coleman, T. R., Westenfelder, C., Tögel, F. E., Yang, Y., Hu, Z., Swenson, L., Leuvenink, H. G. D., Ploeg, R. J., d’Uscio, L. V., Katusic, Z. S., Ghezzi, P., Zanetti, A., Kaushansky, K., Fox, N. E., Cerami, A., & Brines, M.
- Affiliations
- Verona Pharma (United Kingdom) (GB)
- University of Utah (US)
- Departments of Medicine and Physiology, University of Utah and Veterans Affairs Medical Centers, Salt Lake City, UT 84148;
- University of Groningen (NL)
- Mayo Clinic (US)
- University of Groningen, 9700 AB, Groningen, The Netherlands;
- Mario Negri Institute for Pharmacological Research (IT)
- University of California San Diego (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2006-04-11
- Volume
- 103
- Issue
- 15
- Pages
- 5965-5970
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2106292297
- Cited by
- 127
- References
- 62
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 6 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 3 · 2014: 5 · 2013: 9 · 2012: 7
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- National Cancer Institute (R01CA031615)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- recombinant human erythropoietin, carbamylated erythropoietin, erythropoietin receptor, heteromeric receptors, procoagulant activity, platelet count, blood pressure, renal blood flow, sodium excretion, tissue protection, thrombosis, dose-dependent adverse effects, paracrine effects
- MeSH terms
- Animals, Blood Coagulation, Blood Pressure, Bone Marrow Cells, Cell Line, Coagulants, Endothelium, Vascular, Erythropoietin, Hematopoiesis, Hemodynamics, Humans, Renal Circulation, Stem Cells, Umbilical Veins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. https://app.cochat.ai/papers/10.1073/pnas.0601377103
- The paper
- Coleman, T. R., Westenfelder, C., Tögel, F. E., Yang, Y., Hu, Z., Swenson, L., Leuvenink, H. G. D., Ploeg, R. J., d’Uscio, L. V., Katusic, Z. S., Ghezzi, P., Zanetti, A., Kaushansky, K., Fox, N. E., Cerami, A., & Brines, M. (2006). Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0601377103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.